Omeros
Biopharmaceutical company engaged in discovery, development, and commercialization of small-molecule and protein therapeutics. Research focuses include complement-mediated diseases, central nervous system disorders, oncology, GPCR-targeted discovery, and anti-infective fusion-protein approaches. Operates discovery platforms for orphan GPCR ligand identification and antibody generation, advances clinical- and preclinical-stage programs, maintains regulatory and commercial activities for approved therapeutics, and provides public-facing contact channels for medical information, compassionate use, and partnership inquiries. Publishes peer-reviewed clinical correspondence and maintains documented compliance programs.
Industries
Nr. of Employees
medium (51-250)
Patents
Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome
US-12351648-B2
View DetailsMonoclonal antibodies, compositions and methods for detecting complement factor D
US-12129290-B2
View Details
Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome
US-12351648-B2
View DetailsMonoclonal antibodies, compositions and methods for detecting complement factor D
US-12129290-B2
View DetailsProducts
Narsoplimab (MASP-2 monoclonal antibody)
A fully human monoclonal antibody targeting MASP-2 (lectin pathway effector enzyme) developed for treatment of lectin-pathway mediated diseases, including transplant-associated thrombotic microangiopathy (TA-TMA); marketed in the U.S. as of December 2025.
OMS906 (MASP-3 inhibitor) — clinical-stage asset
Humanized monoclonal antibody inhibitor of MASP-3 (alternative pathway activator) advanced into clinical development for paroxysmal nocturnal hemoglobinuria (PNH); subject to an asset acquisition and license for certain indications by a third party.
OMS1029 (long-acting MASP-2 antibody) — clinical candidate
Second-generation, long-acting antibody targeting MASP-2 intended for less-frequent dosing (subcutaneous or intravenous) to inhibit the lectin complement pathway.
OMS527 (PDE7 small-molecule inhibitor)
Small-molecule phosphodiesterase 7 (PDE7) inhibitor in clinical development for addiction and compulsive disorders, evaluated in Phase 1 and supported by preclinical models showing reduced craving and relapse.
GPCR deorphanization platform (discovery outputs)
Discovery outputs comprising identified ligands and validated orphan GPCR targets across metabolic, cardiovascular, CNS, oncology, and immunologic indications to support target validation and medicinal chemistry.
OMS1029
OMS1029 is a long-acting second-generation antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2).
Narsoplimab (MASP-2 monoclonal antibody)
A fully human monoclonal antibody targeting MASP-2 (lectin pathway effector enzyme) developed for treatment of lectin-pathway mediated diseases, including transplant-associated thrombotic microangiopathy (TA-TMA); marketed in the U.S. as of December 2025.
OMS906 (MASP-3 inhibitor) — clinical-stage asset
Humanized monoclonal antibody inhibitor of MASP-3 (alternative pathway activator) advanced into clinical development for paroxysmal nocturnal hemoglobinuria (PNH); subject to an asset acquisition and license for certain indications by a third party.
OMS1029 (long-acting MASP-2 antibody) — clinical candidate
Second-generation, long-acting antibody targeting MASP-2 intended for less-frequent dosing (subcutaneous or intravenous) to inhibit the lectin complement pathway.
OMS527 (PDE7 small-molecule inhibitor)
Small-molecule phosphodiesterase 7 (PDE7) inhibitor in clinical development for addiction and compulsive disorders, evaluated in Phase 1 and supported by preclinical models showing reduced craving and relapse.
GPCR deorphanization platform (discovery outputs)
Discovery outputs comprising identified ligands and validated orphan GPCR targets across metabolic, cardiovascular, CNS, oncology, and immunologic indications to support target validation and medicinal chemistry.
OMS1029
OMS1029 is a long-acting second-generation antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2).
Expertise Areas
- Complement-mediated disease research and therapeutics
- GPCR deorphanization and orphan GPCR drug discovery
- Monoclonal antibody discovery and biologics development
- Small-molecule CNS drug discovery (PDE7 and GPCR modulators)
Key Technologies
- High-throughput cell-based GPCR screening
- Ex vivo B-cell antibody discovery platforms
- Fusion-protein engineering
- Medicinal chemistry for small-molecule optimization
News & Updates
Peer-reviewed correspondence reporting a clinical case where a MASP-2 pathway inhibitor was used to treat hematopoietic cell transplantation-associated thrombotic microangiopathy (TA-TMA) with improvement in hematologic and renal markers while maintaining GVHD prophylaxis.
Regulatory approval in the U.S. for the MASP-2 monoclonal antibody to treat transplant-associated thrombotic microangiopathy (approved December 2025).
An asset acquisition and licensing agreement was completed for the MASP-3 clinical program in PNH, with the licensee advancing the program in PNH and investigating other rare disorders.
Award of a 3-year $6.69 million grant from the National Institute on Drug Abuse to support preclinical cocaine interaction studies and a randomized inpatient study evaluating a PDE7 inhibitor in cocaine use disorder.
Dosing initiated in a Phase 1 clinical trial to evaluate safety and tolerability of a long-acting MASP-2 inhibitor.
Publication in Bone Marrow Transplantation describing a single-patient case of transplant-associated thrombotic microangiopathy treated with a MASP-2 pathway inhibitor with hematologic and renal recovery.
Peer-reviewed correspondence reporting a clinical case where a MASP-2 pathway inhibitor was used to treat hematopoietic cell transplantation-associated thrombotic microangiopathy (TA-TMA) with improvement in hematologic and renal markers while maintaining GVHD prophylaxis.
Regulatory approval in the U.S. for the MASP-2 monoclonal antibody to treat transplant-associated thrombotic microangiopathy (approved December 2025).
An asset acquisition and licensing agreement was completed for the MASP-3 clinical program in PNH, with the licensee advancing the program in PNH and investigating other rare disorders.
Award of a 3-year $6.69 million grant from the National Institute on Drug Abuse to support preclinical cocaine interaction studies and a randomized inpatient study evaluating a PDE7 inhibitor in cocaine use disorder.
Dosing initiated in a Phase 1 clinical trial to evaluate safety and tolerability of a long-acting MASP-2 inhibitor.
Publication in Bone Marrow Transplantation describing a single-patient case of transplant-associated thrombotic microangiopathy treated with a MASP-2 pathway inhibitor with hematologic and renal recovery.